Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.

Annals of hematology - 7 Mar 2026

Sun Yao, Qin Shanshan, Wang Lu, Yi Hai, Ding Li, Cai Bo, Liu Na, Li Yuhang, Hu Jiangwei, Qiao Zhuoqing, Li Fei, Liu Daihong, Dou Liping, Hu Liangding

Abstract excerpt

TP53 mutations are associated with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure, but outcomes are suboptimal and risk stratification remains challenging. This multi-center, retrospective study analyzed 66 patients with TP53-mutated AML/MDS who underwent allo-HSCT. The study endpoints...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Transplantation, Homologous

Share to Tumor Suppressor Protein p53

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41793509
DOI: 10.1007/s00277-026-06895-4
PMCID: PMC12967432

Genes

TP53
NRM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.PMID 41793509Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationSemantic proximity Read ↗

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.Semantic proximity Read ↗

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.Semantic proximity Read ↗

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDSSemantic proximity Read ↗

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.Semantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

Transplant for TP53-mutated MDS and AML: because we can or because we should?Semantic proximity Read ↗

Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases.Semantic proximity Read ↗

Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts.Semantic proximity Read ↗

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.